We read with interest the Article by Giulio Cavalli and colleagues[@bib1] in *The Lancet Rheumatology* about the use of anakinra for patients with acute respiratory distress syndrome (ARDS) related to COVID-19. Although the study by Cavalli and colleagues was not performed in intensive care units (ICUs), the semantics used by the authors derive from critical care practice and need some precision. First, the definition of ARDS necessitates a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO~2~:FiO~2~) of less than 200 mm Hg for a diagnosis of moderate ARDS and of less than 100 mm Hg for severe ARDS, assessed on invasive mechanical ventilation with a positive end-expiratory pressure of more than 5 cm H~2~O.[@bib2] Individuals included in this study benefited from non-invasive ventilation, which defines the patients as having mild ARDS. Thus, the patients in the study by Cavalli and colleagues had mild ARDS, irrespective of the PaO~2~:FiO~2~ ratio (provided that PaO~2~:FiO~2~ is \<300 mm Hg), and the authors are incorrect to classify the patients as having moderate-to-severe ARDS.

Second, non-invasive ventilation can be used outside the ICU, but only in specific patients, in specialised units with adequate monitoring and skilled and experienced physicians and nurses,[@bib3] which seems to differ from the care reported by Cavalli and colleagues.[@bib1] Consequently, the COVID-19 pandemic context, with a shortage of ICU resources, and the patient severity raise questions about the use of non-invasive ventilation in general wards, and subsequently about the patient outcomes that were compared.

Third, the evolution of PaO~2~:FiO~2~ ratio was assessed with a derivative formula based on oxygen saturation.[@bib4] This formula, which is neither recommended nor used in clinical practice, showed a satisfactory ability to assess a range of PaO~2~:FiO~2~ ratios with the transcutaneous oxygen saturation, but this cannot be used as a surrogate for the PaO~2~:FiO~2~ ratio.

Finally, despite a high rate of bacteraemia, the authors conclude that anakinra has a remarkable safety profile that makes it especially suitable for use in critically ill patients. This assertion remains questionable without additional data focusing on ICU patients, especially those undergoing invasive mechanical ventilation with moderate-to-severe ARDS. Such patients are at increased risk of nosocomial infections, notably ventilator-associated pneumonia,[@bib5] the diagnosis of which could be more difficult in a patient treated with anakinra due to the drug\'s immunosuppressive effect. Indeed, decreases in fever and leucocyte count could delay treatment and have important effects on the attributable mortality of such hospital-acquired infections. In conclusion, further studies are necessary to establish the safety and efficacy profile of the recombinant interleukin-1 receptor antagonist anakinra in patients with ARDS who are hospitalised in the ICU setting.
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